Kezar Life Sciences, Inc.

    Jurisdiction
    United States
    LEI
    549300EV1V8GXBV18004
    ISIN
    US49372L2097 (KZR)
    Sectors
    1. Healthcare
    2. Biotechnology

    Scores

    InsiderPie Expert Score
    trending_flat 50 / 100
    Even with peer group:
    50 / 100
    Fair value (Benjamin Graham formula)
    N/A
    Financial strength (Piotroski F-Value)
    3 / 9
    Fundamental strength relative to industry (Mohanram G-Value)
    4 / 7

    Profile

    Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. Read full profile

    Stock price

    Stock price loading... No stock price available Stock price provided by Lang & Schwarz Steigende Zinsen und niedrigere Bewertungen für Wachstumsaktien im Allgemeinen Eine Gewinnwarnung beim Konkurrenten Adyen signalisiert eine Abkühlung des europäischen Markts für Zahlungsdienstleistungen. Eine Gewinnwarnung von Wordline SA triggert einen massiven Kursverlust.

    Configure chart

    Adjust colors to be more accessible for red-green-colorblind users.
    Scale
    Moving average Display a moving average line on the chart.

    Fundamentals

    Net revenue
    €0.00
    Gross margin
    0.0%
    EBIT
    -€64.98M
    EBIT margin
    0.0%
    Net income
    -€60.74M
    Net margin
    0.0%

    Statement period: - (published )

    Dividends

    No dividend payouts

    Earnings Calls

    Latest earnings call: August 9, 2020

    Investor transactions

    Name Shares Value Last change Change type
    Peter Brown 86K $417.65K -2.1K Sell

    Add to watchlist

    Notifications